 Sargramostim was approved by the US FDA in 1991 to accelerate white blood cell recovery following autologous bone marrow transplantation under the trade name Leukine, and passed through several hands, ending up with Genzyme which subsequently was acquired by Sanofi.Leukine is now owned by Partner Therapeutics (PTx).Imlygic was approved by the US FDA in October 2015, and in December 2015 by the EMA, as an oncolytic virotherapy, commercialized by Amgen Inc.